Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
netupitant/palonosetron (Akynzeo®)
Reference No. 1484
Publication date:
27/07/2016
Appraisal information
netupitant/palonosetron (Akynzeo®) 300 mg/0.5 mg capsule
Company:
Chugai Pharma UK Ltd
BNF category:
Central nervous system
NMG meeting date:
08/06/2016
AWMSG meeting date:
13/07/2016
Submission Type:
Full Submission
Status:
Recommended with restrictions
Advice No:
2016
Ratification by Welsh Government:
26/07/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Netupitant/palonosetron (Akynzeo®) is recommended as an option for restricted use within NHS Wales for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatinbased cancer chemotherapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Netupitant/palonosetron (Akynzeo®) is not recommended for use within NHS Wales for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Final Appraisal Recommendation (FAR)
Download
netupitant-palonosetron (Akynzeo) 1484 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
netupitant-palonosetron (Akynzeo) 1484 ASAR
Clinical Expert (CE) Summary
Download
netupitant-palonosetron (Akynzeo) 1484 CE summary
